









Markets
/
Stocks
/
nasdaq-camp
/

CAMP4 Therapeutics Corp

CAMP

3.770USD

-0.170-4.31%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

76.01MMarket Cap

LossP/E TTM



CAMP4 Therapeutics Corp

3.770

-0.170-4.31%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CAMP4 Therapeutics Corp

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CAMP4 Therapeutics Corp's Score

Industry at a Glance

Industry Ranking

26 / 407

Overall Ranking

107 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

8.500

Target Price

+104.33%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

CAMP4 Therapeutics Corp Highlights

StrengthsRisks

CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs initially focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.

Growing

The company is in a growing phase, with the latest annual income totaling USD 652.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 652.00K.

Fairly Valued

The company’s latest PE is -1.51, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 22.65M shares, increasing 37.24% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 328.89K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 7.61, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.61

Change



Financials

9.72

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.91

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.56

Key Metrics

Free cash flow

No Data

CAMP4 Therapeutics Corp's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 7.81, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -1.51, which is -65.73% below the recent high of -0.52 and -194.92% above the recent low of -4.45.

Score

Industry at a Glance

Previous score

7.81

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 26/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for CAMP4 Therapeutics Corp is 7.50, with a high of 12.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Buy

Current Rating

8.500

Target Price

+115.74%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

CAMP4 Therapeutics Corp

CAMP

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 8.92, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 4.50 and the support level at 3.12, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.26

Change

-0.34

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.002

Buy

RSI(14)

57.493

Neutral

STOCH(KDJ)(9,3,3)

69.492

Sell

ATR(14)

0.369

Low Volatility

CCI(14)

54.363

Neutral

Williams %R

34.058

Buy

TRIX(12,20)

1.257

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

3.952

Sell

MA10

3.810

Sell

MA20

3.611

Buy

MA50

2.906

Buy

MA100

2.228

Buy

MA200

2.858

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 112.37%, representing a quarter-over-quarter increase of 23.25%. The largest institutional shareholder is The Vanguard, holding a total of 328.89K shares, representing 1.63% of shares outstanding, with 75.01% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

5AM Ventures

8.81M

+200.91%

Polaris Partners

3.93M

+49.80%

Vivo Capital, LLC

3.92M

Enavate Sciences GP, LLC

3.79M

Fidelity Management & Research Company LLC

3.02M

+397.32%

Northpond Ventures, LLC

2.24M

Andreessen Horowitz

2.13M

HarbourVest Partners, L.L.C.

1.27M

The Vanguard Group, Inc.

Star Investors

328.89K

+40.65%

Mandel-Brehm (Josh)

278.42K

+2.23%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 1.51, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.